Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 30, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2024

Conditions
Exudative Age Related Macular Degeneration
Interventions
DRUG

Ranibizumab

Intravitreal injection 0.5 MG Per 0.05 ML Injection.

DEVICE

Photodynamic laser treatment (PDT)

PDT light dose of 50 J/cm2 of neovascular lesion administered at an intensity of 600mW/cm2. A Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area. PDT will be administered at half-fluence - measured by time, i.e. 42 seconds as opposed to full-fluence which is 83 seconds.

DRUG

Triamcinolone Acetonide

Intravitreal injection of 0.5ml-2mg

DRUG

verteporfin

Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area.

Trial Locations (1)

27157

Wake Forest Health Sciences, Winston-Salem

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Modulight

UNKNOWN

lead

Wake Forest University Health Sciences

OTHER